Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
Scienture Holdings (NASDAQ: SCNX) announced that Dr. Narasimhan Mani, President of Scienture, will participate as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) in India. The conference is scheduled for January 23-25, 2025, at BITS Pilani, Hyderabad Campus.
Dr. Mani will present on the specialty pharmaceutical industry, focusing on technology-driven product innovations and efficient market strategies for improving patient access to novel therapies. He will also participate in panel discussions about global pharmaceutical industry trends, portfolio development, breakthrough technology platforms, and commercialization strategies.
Scienture Holdings (NASDAQ: SCNX), a specialty pharma company focused on novel brand products, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company's management team will present their corporate strategy and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth plans, and investment opportunities.
Scienture (NASDAQ: SCNX) announced that the U.S. Patent and Trademark Office has issued a new patent (No. 12,156,869) for its product SCN-102, a Losartan Potassium Oral Suspension. This patent, along with the previously granted patent No. 11,890,273, covers stable liquid pharmaceutical compositions of Losartan and treatment methods. Both patents extend protection through 2041.
The company's SCN-102 product, currently under FDA review, aims to provide a ready-to-use oral liquid formulation of Losartan, one of the most widely prescribed molecules in its class. The patents demonstrate Scienture's development capabilities and commitment to addressing underserved patient needs.
Scienture Holdings (NASDAQ: SCNX) has secured two strategic financing arrangements: a private placement of 10% secured convertible debentures worth up to $12.22 million to be issued in three tranches to Arena Investors affiliates, and a $50 million equity line of credit (ELOC) agreement with Arena Business Solutions. The first tranche of approximately $3.33 million in debentures was completed on November 25, 2024. Dawson James Securities served as the sole placement agent. The ELOC allows Scienture to issue and sell up to $50 million in common stock over 36 months, though the company has no immediate plans to utilize it. Proceeds will support working capital and general corporate purposes.
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX", effective September 23, 2024. The company will continue to trade on the Nasdaq Stock Market. Scienture Holdings, Inc., through its wholly owned subsidiaries Scienture and Integra Pharma Solutions, , is a comprehensive pharmaceutical product company focused on providing novel specialty products to meet unmet market needs.
The company's products are in development across various therapeutic areas and indications, catering to different market segments and channels. The executive team and board of directors consist of experienced industry veterans, including Suren Ajjarapu as CEO and Chairman, Prashant Patel as President, Interim CFO and COO, and other accomplished members.